Scarica l'app Stockscreener
1.74
3.33%
-0.06
Precedente Chiudi:
$1.80
Aprire:
$1.82
Volume 24 ore:
2.68M
Relative Volume:
0.81
Capitalizzazione di mercato:
$490.66M
Reddito:
-
Utile/perdita netta:
$-225.14M
Rapporto P/E:
-0.8878
EPS:
-1.96
Flusso di cassa netto:
$-192.27M
1 W Prestazione:
-3.33%
1M Prestazione:
+11.54%
6M Prestazione:
+21.68%
1 anno Prestazione:
+114.26%
Intervallo 1D:
$1.72
$1.86
Intervallo di 1 settimana:
$1.72
$2.04
Portata 52W:
$0.46
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Nome
Invivyd Inc
Settore
Industria
Telefono
(781) 819-0080
Indirizzo
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.74 | 490.66M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-22 | Iniziato | BTIG Research | Buy |
| 2025-11-25 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-10-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-26 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Invivyd Inc Borsa (IVVD) Ultime notizie
Invivyd (IVVD) Q4 2025 Earnings Call Transcript - AOL.com
FY2027 Earnings Estimate for Invivyd Issued By HC Wainwright - MarketBeat
Invivyd (NASDAQ:IVVD) Stock Price Up 6.3%Still a Buy? - MarketBeat
Invivyd appoints Michael Mina as chief medical officer - Investing.com Nigeria
Invivyd, Inc. (NASDAQ:IVVD) Q4 2025 Earnings Call Transcript - Insider Monkey
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Rating of "Hold" from Analysts - MarketBeat
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances By Investing.com - Investing.com Canada
Invivyd earnings beat by $0.11, revenue topped estimates - Investing.com Australia
Invivyd Q4 Earnings Call Highlights - MarketBeat
Michael Mina Appointed Chief Medical Officer at Invivyd - geneonline.com
Invivyd appoints Michael Mina as chief medical officer By Investing.com - Investing.com Australia
Invivyd Q4 2025 slides: revenue surges 31%, pipeline advances - Investing.com Nigeria
Invivyd Names Michael Mina Chief Medical Officer - Contract Pharma
Invivyd, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Invivyd Appoints Michael Mina, M.D., Ph.D. as Chief Medical Officer - citybiz
Earnings call transcript: Invivyd Q4 2025 shows robust growth and strategic expansion - Investing.com
Invivyd Advances VYD2311 With Key Phase 3 Alignments - TipRanks
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - The Globe and Mail
Invivyd 2025 10-K: Revenue $53.4M, Net Loss $52.5M - TradingView
Invivyd FY revenue rises; operating expenses cut sharply - TradingView
Michael Mina named chief medical officer, Invivyd, Inc. announces - Traders Union
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - The Manila Times
COVID testing voice Michael Mina now steering antibody drug effort - Stock Titan
Invivyd's Fourth Quarter 2025: Market Achievements Reflected in Valuation, Uneven Pipeline Risk - Bitget
An Overview of Invivyd's Earnings - Benzinga
Invivyd (IVVD) to Release Earnings on Thursday - MarketBeat
Invivyd Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Invivyd (IVVD): Post-Data Plunge, Cash Runway And Next Catalysts For US Traders - AD HOC NEWS
IVVD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - The Manila Times
Invivyd (NASDAQ:IVVD) Earns "Buy" Rating from BTIG Research - MarketBeat
Analysts Offer Insights on Healthcare Companies: US Physical Therapy (USPH) and Invivyd (IVVD) - The Globe and Mail
New study maps COVID protection to antibody levels, not variants - Stock Titan
Aug Breakouts: Is Eaton Vance Senior Income Trust gaining market share2025 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
Lobbying Update: $20,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd (IVVD) CHRO Green sells $63k in stock after option exercise - Investing.com India
Invivyd (IVVD) CFO Duke sells shares worth $63,350 - Investing.com UK
Invivyd CSO Allen sells shares worth $58,600 By Investing.com - Investing.com Nigeria
Invivyd CSO Allen sells shares worth $58,600 - Investing.com South Africa
Invivyd Inc Azioni (IVVD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):